行情

MBRX

MBRX

Moleculin
NASDAQ

实时行情|Nasdaq Last Sale

1.530
-0.150
-8.93%
盘后: 1.560 +0.03 +1.96% 19:55 01/21 EST
开盘
1.670
昨收
1.680
最高
1.680
最低
1.511
成交量
34.08万
成交额
--
52周最高
8.78
52周最低
1.511
市值
4,372.29万
市盈率(TTM)
-2.0441
分时
5日
1月
3月
1年
5年
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, C...
PR Newswire · 2天前
Moleculin Announces Updated Preliminary Safety Data For Annamycin In Its 3 Phase 1 Clinical Trials For Acute Myeloid Leukemia And Metastases Of Soft Tissue Sarcoma
 Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and
Benzinga · 4天前
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported that it has received an updated independ...
PR Newswire · 4天前
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully ...
ACCESSWIRE · 01/12 15:35
Moleculin to Present at the H.C. Wainwright BioConnect Conference
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief ...
PR Newswire · 01/07 13:30
BRIEF-Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
reuters.com · 2021/12/27 13:40
BRIEF-Moleculin Biotech Inc- On Dec 20, Co Amended Its Sublicense Agreement With WPD Pharmaceuticals, Originally Entered Into On Feb 19, 2019
reuters.com · 2021/12/27 13:37
Moleculin Announces Preliminary Third Cohort Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For The Treatment Of Soft Tissue Sarcoma Lung Metastases
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Benzinga · 2021/12/27 13:10
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MBRX最新的财务预测,通过MBRX每股收益,每股净资产,每股现金流等数据分析Moleculin近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测MBRX价格均价为19.00,最高价位29.00,最低价为10.00。
最高29.00
均价19.00
最低10.00
现价1.530
EPS
实际EPS
预期EPS
-0.46-0.35-0.23-0.12
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 46
机构持股: 312.61万
持股比例: 10.94%
总股本: 2,857.71万
类型机构数股数
增持
5
4.96万
建仓
2
2.25万
减持
8
2.35万
平仓
9
17.07万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
暂无数据
暂无数据
MBRX 简况
Moleculin Biotech Inc是一家处于临床阶段的制药公司。该公司专注于通过开发候选药物治疗耐药性癌症和病毒。该公司拥有三条产品线:安那霉素、WP1066、WP1122。安那霉素用于治疗复发或难治性急性髓系白血病(AML)。WP1066是一种免疫或转录调节剂,能够通过抑制调节性t细胞(TRegs)的错误活性来刺激肿瘤免疫反应,同时也抑制关键的致癌转录因子,包括p-STAT3,c-Myc和HIF-1α。WP1122是一种2-脱氧-D-葡萄糖(2-DG)的前药,利用肿瘤细胞相对于健康细胞对葡萄糖的过度依赖来切断肿瘤的燃料供应。

微牛提供Moleculin Biotech Inc(NASDAQ-MBRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MBRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MBRX股票基本功能。